Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
Negma Group has converted 322convertible bonds in Oxurion resulting in a EUR 805,000capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion.
Leuven, BELGIUM,Boston, MA, US–December2, 2022– 07.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following (i) the issuance of 63,550,419 new ordinary shares on November 28, 2022, for a total amount of EUR 605,000, as the result of the conversion of 242 class B convertible bonds, and (ii) the issuance of 21,008,403 new ordinary shares on November 30, 2022, for a total amount of EUR 200,000, as the result of the conversion of 80 class B convertible bonds, pursuant to the Capital Commitment entered into with Negma Group.
Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 290,273,241, outstanding ordinary shares carrying voting rights (compared to 205,714,419 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.
Therefore, Oxurion publishes the following updated information:
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
For further information please contact:
Chief Executive Officer
Tel: +32 16 75 13 10
Chief Business Officer
Tel: +32 16 75 13 10
Tel: +1 617 835 9304
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Vereniging Aegon to participate in current share buyback program8.12.2023 20:00:00 CET | Press release
The Hague, December 8, 2023 - Aegon has entered into an agreement with its largest shareholder, Vereniging Aegon, to partially participate in Aegon’s current EUR 1.5 billion share buyback program. The repurchase of shares from Vereniging Aegon will commence as soon as Aegon has repurchased shares for an amount of EUR 750 million under the buyback program and is expected to run until the end of the share buyback program. Barring unforeseen circumstances, the share buyback is expected to be completed on or before June 30, 2024. As of December 7, Aegon has repurchased 149.8 million shares representing EUR 703.9 million. Aegon began its EUR 1.5 billion share buyback program on July 6, 2023 following the completion of the transaction to combine Aegon’s Dutch pension, life and non-life insurance, banking, and mortgage origination activities with a.s.r., that was announced on July 4, 2023. Vereniging Aegon will participate pro-rata in the share buyback program based on its combined common sha
Clean Motion AB skriver under projektavtal med EU8.12.2023 19:09:01 CET | Pressemelding
Elfordonstillverkaren Clean Motion AB har skrivit under ett projektavtal inom EU Horizon Europe programmet. Projektet GIANTS (Green Intelligent Affordable Nano Transport Solutions) har totalt 23 projektpartners och en total budget på 15,1 miljoner Euro varav 12 miljoner Euro är bidrag från EU. Clean Motion har den tredje största budgeten och kommer att tilldelas ett bidrag från EU på 1,3 miljoner Euro fördelat över projektperioden på 42 månader, med start i januari 2024. Clean Motion AB, en ledare inom utvecklingen av hållbara transportlösningar, är stolta över att meddela sitt deltagande i GIANTS-projektet, finansierat av EU inom ramen för Horizon Europe-programmet. Projektets totala budget uppgår till 15,1 miljoner euro där EU står för 12 miljoner euro. Clean Motions totala budget i projektet är 1,9 miljoner euro med EU-finansiering om 1,3 miljoner euro. Inom projektet som löper från januari 2024 och 42 månader framåt kommer vi att samarbeta med 22 andra partners, bland andra Renault
Wolters Kluwer again recognized as a Leader in Gartner® Magic Quadrant™ for Financial Planning Software8.12.2023 17:50:33 CET | Press release
PRESS RELEASE Wolters Kluwer again recognized as a Leader in Gartner® Magic Quadrant™ for Financial Planning Software Wolters Kluwer CCH Tagetik AI-based financial planning solution empowers finance professionals to make faster and better-informed decisions. New York – Dec. 8, 2023 – Wolters Kluwer, a global leader in professional information, software solutions and services, today announced that it has been recognized as a Leader in the 2023 Gartner Magic Quadrant for Financial Planning Software. Earlier this month, Wolters Kluwer also received recognition as a Leader in the Gartner Magic Quadrant for Financial Close and Consolidation Software. CCH Tagetik Budgeting, Planning and Forecasting software is Wolters Kluwer’s AI-based, enterprise-wide planning solution, which helps global companies facilitate strategic, financial, and operational planning, including supply chain, workforce, and capital expenses. The solution, which supports customers across vertical industries, is particula
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment8.12.2023 17:50:00 CET | Press release
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programme Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (eBC) who have residual invasive disease following neoadjuvant (before surgery) treatment. A statistically significant and clinically meaningful improvement in overall survival (OS), a secondary endpoint, was observed with adjuvant (post-surgery) Kadcyla® (trastuzumab emtansine) compared to Herceptin® (trastuzumab): at the 7-year landmark OS rates were 89.07% and 84.37
Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation8.12.2023 17:45:00 CET | Press release
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5 These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authorities Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance®) and fulvestrant as a first-line treatment for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.1 The inavolisib combination reduced the risk of disease worsening or death (progression-free survival; PFS) by 57% compared to palbociclib and fulvestrant alone (15.0 months vs 7.3 months;